Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.

Androgen receptor signaling is the predominant driver of prostate cancer's natural history, underpinning the rationale for AR-targeted therapies.

• The pivotal role of the AR pathway underscores the rationale for targeting AR activity in therapeutic strategies.
• The review analyzes the evolving role of second-generation androgen receptor signaling inhibitors (ARSIs) in the management of both non-metastatic and metastatic castration-resistant prostate cancer (CRPC).
• PubMed literature research using keywords related to castration-resistant prostate cancer and its treatments was performed, including the most relevant trials and reviews.

Second-generation ARSIs have become the cornerstone of current treatment paradigms for castration-resistant prostate cancer.

• ARSIs have revolutionized the management of prostate cancer, providing substantial clinical benefits.
• The review covers ARSIs in both non-metastatic and metastatic castration-resistant prostate cancer settings.
• ARSIs represent the cornerstone of current treatment paradigms according to the authors' analysis.

Resistance mechanisms to ARSIs have emerged as a significant clinical challenge, necessitating novel therapeutic strategies.

• The development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.
• The review critically examines mechanisms underlying treatment resistance.
• Novel agents targeting resistance pathways are among the emerging strategies under investigation.

Emerging combination strategies involving ARSIs and novel agents targeting resistance pathways are under active investigation.

• The review critically examines emerging combination strategies involving ARSIs and novel agents targeting resistance pathways.
• Ongoing trials are investigating novel hormonal-axis-directed agents and innovative combination therapies.
• These approaches aim to expand the arsenal of effective treatments for resistant prostate cancer.

Biomarker-driven approaches are identified as critical for refining patient selection and improving therapeutic outcomes in CRPC.

• Biomarker-driven approaches are described as 'critical for refining patient selection and improving therapeutic outcomes.'
• Key challenges include tailoring therapies to specific molecular subtypes.
• The review provides insights into future directions for enhancing outcomes, emphasizing the need for molecular stratification.

Optimal treatment sequencing and overcoming resistance remain key unresolved challenges in the management of castration-resistant prostate cancer.

• Key challenges include 'determining optimal treatment sequencing, overcoming resistance mechanisms, and tailoring therapies to specific molecular subtypes.'
• The review addresses both non-metastatic and metastatic CRPC settings, suggesting sequencing complexity across disease stages.
• Future directions for enhancing outcomes are discussed in the context of these ongoing challenges.